Drugs Made In America Acquisition II Balance Sheet
NASDAQ: DMIIFinanceBlank ChecksUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Drugs Made In America Acquisition II financial position
At the end of fiscal 2025, Drugs Made In America Acquisition II reported total assets of $505.0 million against total liabilities of $17.8 million. Shareholders' equity was negative at -$17.8 million, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $223 in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 0.09, meaning short-term obligations exceed short-term assets.
Summary generated from market data by MetaCap's automated system. Methodology
Drugs Made In America Acquisition II balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 |
|---|---|
| Cash & Equivalents | 223 |
| Total Current Assets | 26.04K |
| Total Assets | 504.96M |
| Accounts Payable | 99.36K |
| Total Current Liabilities | 300.86K |
| Total Liabilities | 17.80M |
| Shareholders' Equity | -17.77M |
| Retained Earnings | -17.78M |
| Net Cash (Debt) | 223 |
| Shares Outstanding | 13.70M |
Values in USD; B = billions, M = millions. Fiscal periods follow DMII's reporting calendar. What is a balance sheet?